29 Apr
2024
15:05 E.S.T.

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

Read more

22 Apr
2024
11:16 E.S.T.

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Read more

10 Apr
2024
10:26 E.S.T.

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

Read more

08 Apr
2024
05:37 E.S.T.

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

Read more

16 Jan
2024
16:30 E.S.T.

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

Read more

22 Dec
2023
16:30 E.S.T.

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

Read more

17 Nov
2023
16:30 E.S.T.

Cellectis’ Shareholders Meeting to be Held on December 22, 2023

Read more

15 Nov
2023
02:30 E.S.T.

Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

Read more

06 Nov
2023
16:30 E.S.T.

Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

Read more

02 Nov
2023
16:30 E.S.T.

Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting

Read more